Developing precision medicines for kidney diseases

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.

Read More


Visit our news page for the latest press releases

Read More

January 12, 2022

Download the latest Chinook Corporate Presentation

Read More

Atrasentan Update

The atrasentan phase 3 ALIGN clinical trial is enrolling patients with IgA nephropathy and the atrasentan phase 2 AFFINITY clinical trial is enrolling patients with proteinuric glomerular diseases.

Read More


Advancing a pipeline of precision medicines for kidney diseases.

Our lead pipeline candidates target rare, severe kidney disorders with few currently approved therapies.


mobile pipeline

Learn More